Ad
SELB - Selecta Biosciences Stock Trading
About | Selecta Biosciences Inc. (NASDAQ:SELB)
None
Quote | Selecta Biosciences Inc. (NASDAQ:SELB)
| Last: | $1.14 |
|---|---|
| Change Percent: | -1.8% |
| Open: | $1.13 |
| Close: | $1.14 |
| High: | $1.16 |
| Low: | $1.095 |
| Volume: | 463,980 |
| Last Trade Date Time: | 09/27/2023 03:00:00 am |
News | Selecta Biosciences Inc. (NASDAQ:SELB)
-
2023-08-17 07:58:15 ET More on Selecta Biosciences Selecta surges ~20% as gout drug SEL-212 meets main goal in 2 phase 3 trials Selecta Biosciences stock rises 10% on license deal with Astellas for Xork For further details see: Selecta Biosciences GAAP EPS of -$0...
-
– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 – – Company to suspend further investment in majority of pipeline; evaluating potential licen...
Message Board Posts | Selecta Biosciences Inc. (NASDAQ:SELB)
| Subject | By | Source | When |
|---|---|---|---|
| Very interesting on no news? | subslover | investorshub | 03/21/2023 11:43:45 AM |
| On June 22, 2022, Selecta Biosciences, Inc. (the | subslover | investorshub | 06/23/2022 2:07:19 PM |
| I believe we are watching a beginning of | robertus | investorshub | 06/16/2022 9:56:11 PM |
| Anybody here? Things are picking up. | m1ocha | investorshub | 06/16/2022 1:06:48 PM |
| No comments since May. Is anyone monitoring | VApopeye | investorshub | 10/21/2021 3:40:25 PM |
Selecta Biosciences Inc. Company Name:
SELB Stock Symbol:
NASDAQ Market:
Selecta Biosciences Inc. Website:
Ad
-
– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 – – Company to suspend further investment in majority of pipeline; evaluating potential licen...
-
- Phase 3 DISSOLVE I and DISSOLVE II studies both met their primary efficacy endpoints, with SEL-212-treated patients demonstrating statistically significant higher response rates compared to placebo - - SEL-212 was observed to have a favorable safety profile and was well-tolerated acro...
-
SELB - Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
- Company to implement capital prioritization initiative, extending cash runway to 2H-2025 - - $127.5 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2023 - - Reported positive data from Phase 3 DISSOLVE program of SEL-212 ...